Isolated Limb Perfusion in the Treatment of Advanced Soft-tissue Sarcomas

  • Joseph M. Klausner
  • Dina Lev-Chelouche
  • Isaac Meller
  • Moshe Inbar
  • Mordechai Gutman


Isolate Limb Perfusion Limb Volume Perfusion Flow Rate Extremity Sarcoma Left Ventricular Stroke Work Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Creech O, Krementz ET, Ryan RF et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–31.PubMedGoogle Scholar
  2. 2.
    Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet. 1969;129:305–8.PubMedGoogle Scholar
  3. 3.
    Lienard D, Ewaienko P, Delmotti JJ et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992; 10:52–60.PubMedGoogle Scholar
  4. 4.
    Wieberdink J, Benckhuysen C, Braat RP et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur Cancer Clin Oncol. 1982;18:905–10.Google Scholar
  5. 5.
    Sorkin P, Abu-Abid S, Lev D et al. Systemic leakage and side effects of tumor necrosis factor administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg. 1995;130:1079–84.PubMedGoogle Scholar
  6. 6.
    Barker WC, Andrich MP, Alexander HR et al. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med. 1995;22:1242–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Thom AK, Alexander HR, Andrich MP et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. J Clin Oncol. 1995;13:264–73.PubMedGoogle Scholar
  8. 8.
    Eggermont AMM, Schraffordt-Koops H, Klausner JM et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft-tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg. 1996;224:756–65.CrossRefPubMedGoogle Scholar
  9. 9.
    Briele HA, Dyuric M, Jung DT et al. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res. 1985;45:1885–9.PubMedGoogle Scholar
  10. 10.
    Ghussen F, Kruger I, Groth W et al. The role of hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer. 1988;61:654–9.PubMedGoogle Scholar
  11. 11.
    Hafstrom L, Rudenstam CM, Blomquist E et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent melanoma of the extremities. J Clin Oncol. 1991;9:2091–4.PubMedGoogle Scholar
  12. 12.
    Lienard D, Eggermont AM, Kroon BBR et al. Isolated limb perfusion in primary and recurrent melanoma: Indications and results. Semin Surg Oncol. 1998;14:202–9.PubMedGoogle Scholar
  13. 13.
    Klaase JM, Kroon BBR, Benckhuysen C et al. Results of regional isolation perfusion with cytostatics in patients with soft-tissue tumors of the extremities. Cancer. 1989;64: 616–21.PubMedGoogle Scholar
  14. 14.
    Aggarwal BB, Kohr WJ, Hass PE et al. Human tumor necrosis factor: production, purification and characterization. Biol Chem. 1985;260:2345–54.Google Scholar
  15. 15.
    Bevilcqua MP, Pober JS, Majeau GR et al. Recombinant tumor necrosis factor induces coagulant activity in cultured human vasculature endothelium; characterization and comparison with actions of interleukin-1. Proc Natl Acad Sci USA. 1986;83:4533–7.Google Scholar
  16. 16.
    Alexander HR, Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Semin Surg Oncol. 1996;12:416–26.CrossRefPubMedGoogle Scholar
  17. 17.
    Cheresh DA. Death to a blood vessel, death to a tumor. Nature Med. 1998;4:395–8.PubMedGoogle Scholar
  18. 18.
    Ruegg C. Evidence for the involvement of endothelial cell integrin α/β3 in the disruption of the tumor vasculature induced by TNF and IFN-γ Nature Med. 1998;4:408–14.PubMedGoogle Scholar
  19. 19.
    Regeness A, Muller M, Curschellas E et al. Antitumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer. 1987;39:266–73.Google Scholar
  20. 20.
    Watanabe N, Niitso Y, Umeno N et al. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res. 1988;48: 650–3.PubMedGoogle Scholar
  21. 21.
    Vrouenraets BC, Klaase JM, Kroon BB et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg. 1995; 130:43–7.PubMedGoogle Scholar
  22. 22.
    Klaase JM, Kroon BB, van Slooten GW et al. Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma. Reg Cancer Treat. 1992;4:309–12.Google Scholar
  23. 23.
    Gutman M, Inbar M, Shlush-Lev D et al. High dose tumor necrosis factor alpha and melphalan administered via isolated limb perfusion for advanced soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79:1129–37.CrossRefPubMedGoogle Scholar
  24. 24.
    Hoekstra HJ, Naujocks T, Schraffordt Koops Het et al. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results. Reg Cancer Treat. 1992;4:301–4.Google Scholar
  25. 25.
    Gaynor JJ, Tan CC, Casper ES et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol. 1992; 10:1317–27.PubMedGoogle Scholar
  26. 26.
    Lawrence W, Donegan WL, Natrajan N et al. Adult soft-tissue sarcomas; a pattern of care survey of the American College of Surgeons. Ann Surg. 1987;205:349–59.PubMedGoogle Scholar
  27. 27.
    Eilber FR, Eckhardt JF, Rosen G et al. Neoadjuvant chemotherapy and radiotherapy in the multidisciplinary management of soft-tissue sarcomas of the extremity. Surg Oncol Clin N Am. 1993;2:611–20.Google Scholar
  28. 28.
    Krementz ET, Carter RD, Sutherland CM et al. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg. 1977;185:555–64PubMedGoogle Scholar
  29. 29.
    Sijens PE, Eggermont AMM, Van Dijk P et al. 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcoma treated by single dose TNF-alpha and melphalan isolated limb perfusion. NMR Biomed. 1995;8:215–21.PubMedGoogle Scholar
  30. 30.
    Nieweg OF, Prulm J, Hoekstra HY et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med. 1994; 35:90–2.PubMedGoogle Scholar
  31. 31.
    Vaglini M, Belli F, Ammatuna M et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high dosealpha-tumor necrosis factor gamma interferon and melphalan. Cancer. 1994;73:483–92.PubMedGoogle Scholar
  32. 32.
    Lev D, Abu-Abid S, Kollander Y et al. Multifocal soft tissue sarcoma limb salavage following isolated limb perfusion with tumor necrosis factor and melphalan. J Surg Oncol. 1999;70:185–98.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Joseph M. Klausner
  • Dina Lev-Chelouche
  • Isaac Meller
  • Moshe Inbar
  • Mordechai Gutman

There are no affiliations available

Personalised recommendations